CY1111913T1 - Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου - Google Patents

Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου

Info

Publication number
CY1111913T1
CY1111913T1 CY20111100955T CY111100955T CY1111913T1 CY 1111913 T1 CY1111913 T1 CY 1111913T1 CY 20111100955 T CY20111100955 T CY 20111100955T CY 111100955 T CY111100955 T CY 111100955T CY 1111913 T1 CY1111913 T1 CY 1111913T1
Authority
CY
Cyprus
Prior art keywords
combination
stable dosage
zinc
treatment
hydroxyapatite
Prior art date
Application number
CY20111100955T
Other languages
Greek (el)
English (en)
Inventor
Freixedas Félix Grases
Bestard Joan Perelló
Amengual Bernat Isern
Cortés Pilar Sanchís
Almirall Rafael M Prieto
Bauza Antonia Costa
Original Assignee
Universitat De Les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat De Les Illes Balears filed Critical Universitat De Les Illes Balears
Publication of CY1111913T1 publication Critical patent/CY1111913T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Catalysts (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)
CY20111100955T 2006-02-17 2011-10-06 Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου CY1111913T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200600377A ES2280136B1 (es) 2006-02-17 2006-02-17 Asociacion a dosis fija de fitato y zinc.
EP07726369A EP1984001B1 (en) 2006-02-17 2007-02-14 Fixed-dose association of phytate and zinc

Publications (1)

Publication Number Publication Date
CY1111913T1 true CY1111913T1 (el) 2015-11-04

Family

ID=38007006

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100955T CY1111913T1 (el) 2006-02-17 2011-10-06 Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου

Country Status (18)

Country Link
US (2) US8377908B2 (enrdf_load_stackoverflow)
EP (1) EP1984001B1 (enrdf_load_stackoverflow)
JP (2) JP5554499B2 (enrdf_load_stackoverflow)
CN (1) CN101384266B (enrdf_load_stackoverflow)
AT (1) ATE516035T1 (enrdf_load_stackoverflow)
AU (1) AU2007216453B2 (enrdf_load_stackoverflow)
BR (1) BRPI0707008A2 (enrdf_load_stackoverflow)
CA (1) CA2641216C (enrdf_load_stackoverflow)
CY (1) CY1111913T1 (enrdf_load_stackoverflow)
DK (1) DK1984001T3 (enrdf_load_stackoverflow)
ES (1) ES2280136B1 (enrdf_load_stackoverflow)
MX (1) MX2008010502A (enrdf_load_stackoverflow)
NO (1) NO341286B1 (enrdf_load_stackoverflow)
PL (1) PL1984001T3 (enrdf_load_stackoverflow)
PT (1) PT1984001E (enrdf_load_stackoverflow)
RU (1) RU2415673C2 (enrdf_load_stackoverflow)
SI (1) SI1984001T1 (enrdf_load_stackoverflow)
WO (1) WO2007093611A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.
AU2011373141B2 (en) * 2011-07-12 2015-12-10 The Procter & Gamble Company Oral care compositions comprising phytic acid
ES2486441B1 (es) * 2014-04-02 2015-06-11 Universitat De Les Illes Balears Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico
CA2971579C (en) 2014-12-26 2022-10-04 Colgate-Palmolive Company Zinc phosphate complex for oral care
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
CN108444985B (zh) * 2018-04-25 2021-02-02 山西省食品药品检验所(山西省药品包装材料监测中心) 一种肾精子icp-ms鉴别方法及应用
US20210347793A1 (en) * 2018-09-18 2021-11-11 Inositec Ag Calcium oxalate crystallization inhibitors for renal disorders
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934001A (en) 1965-12-07 1976-01-20 Lever Brothers Company Oral compositions containing germicidally active plastic powders
NL149701C (nl) 1965-12-08 1981-05-15 Procter & Gamble Werkwijze voor het bereiden van een tegen tandsteen werkzaam tandverzorgingsmiddel, dat als werkzaam bestanddeel een fosfonzuurderivaat bevat, alsmede gevormd tandverzorgingsmiddel.
US3934002A (en) 1972-06-30 1976-01-20 The Procter & Gamble Company Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies
US4215105A (en) 1978-10-27 1980-07-29 Colgate-Palmolive Company Anticalculus oral composition
JPS5846483B2 (ja) 1979-09-20 1983-10-17 ライオン株式会社 口腔用組成物
JPS5835965B2 (ja) * 1979-07-31 1983-08-05 ライオン株式会社 口腔用組成物
JPS6043322B2 (ja) * 1979-09-05 1985-09-27 ライオン株式会社 口腔用組成物
US4515772A (en) 1982-06-22 1985-05-07 The Procter & Gamble Company Oral compositions
US4808409A (en) 1984-08-16 1989-02-28 Board Of Trustees, University Of Illinois Low cariogenic sweetening agents
JPS6229526A (ja) * 1985-08-01 1987-02-07 Wakamoto Pharmaceut Co Ltd 高カルシウム尿症の治療及び予防剤
US4627977A (en) 1985-09-13 1986-12-09 Colgate-Palmolive Company Anticalculus oral composition
US4808401A (en) 1985-09-13 1989-02-28 Colgate-Palmolive Company Anticalculus oral composition
JPH0729909B2 (ja) * 1986-11-28 1995-04-05 ライオン株式会社 口腔用組成物
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
ES2007238A6 (es) * 1988-06-17 1989-06-01 Univ Illes Balears Procedimiento para la preparacion de fitato-zn (ii)>
US5300289A (en) * 1991-12-10 1994-04-05 The Dow Chemical Company Phytate antimicrobial compositions in oral care products
US5286479A (en) * 1991-12-10 1994-02-15 The Dow Chemical Company Oral compositions for suppressing mouth odors
CN1102978A (zh) * 1993-11-23 1995-05-31 姚焕新 多功能牙膏
JPH08104635A (ja) * 1994-10-06 1996-04-23 Ichimaru Pharcos Co Ltd フィチン酸亜鉛を有効成分とする外用製剤
JPH10182383A (ja) * 1996-12-24 1998-07-07 Lion Corp 口腔用組成物
IT1306133B1 (it) * 1999-04-22 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
JP2004065249A (ja) * 2002-06-13 2004-03-04 Fumio Hara フィチン酸、イノシトールおよびナイアシンの富化方法、食品の製造方法、並びに食品
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
CN1259033C (zh) * 2004-06-24 2006-06-14 江西航天日用化工发展有限责任公司 可去除烟黄斑牙垢的复方牙膏及其制备方法
BRPI0619389A2 (pt) * 2005-11-29 2011-10-04 Procter & Gamble composição dentifrìcia compreendendo um sistema aglutinante que compreende material de argila hidrofìlica
BRPI0620220A2 (pt) * 2005-12-20 2011-11-01 Procter & Gamble composições para tratamento bucal compreendendo zinco e fitato
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.

Also Published As

Publication number Publication date
NO341286B1 (no) 2017-10-02
CN101384266A (zh) 2009-03-11
US8377908B2 (en) 2013-02-19
MX2008010502A (es) 2008-10-23
US20140056994A1 (en) 2014-02-27
JP5554499B2 (ja) 2014-07-23
RU2415673C2 (ru) 2011-04-10
RU2008138358A (ru) 2010-03-27
EP1984001A1 (en) 2008-10-29
JP2014139182A (ja) 2014-07-31
BRPI0707008A2 (pt) 2011-04-12
US20090035232A1 (en) 2009-02-05
WO2007093611A1 (en) 2007-08-23
SI1984001T1 (sl) 2011-12-30
US9144578B2 (en) 2015-09-29
AU2007216453B2 (en) 2012-09-27
NO20083901L (no) 2008-09-11
JP5908933B2 (ja) 2016-04-26
PL1984001T3 (pl) 2012-02-29
JP2009526818A (ja) 2009-07-23
ES2280136B1 (es) 2008-08-16
CN101384266B (zh) 2013-03-20
CA2641216C (en) 2014-04-15
CA2641216A1 (en) 2007-08-23
ES2280136A1 (es) 2007-09-01
PT1984001E (pt) 2011-10-18
AU2007216453A1 (en) 2007-08-23
EP1984001B1 (en) 2011-07-13
ATE516035T1 (de) 2011-07-15
DK1984001T3 (da) 2011-11-07

Similar Documents

Publication Publication Date Title
CY1111913T1 (el) Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου
CY1123852T1 (el) Αλατα ή συγκρυσταλλοι της 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BR112015015898A8 (pt) composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
CY1114272T1 (el) Υποκατεστημενες διυδροπυραζολονες για την θεραπευτικη αντιμετωπιση των καρδιαγγειακων και αιματολογικων παθησεων
CY1118311T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
EA200900044A1 (ru) Замещенные производные 1,3-дифенилпропана, получение и их применение
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CY1126082T1 (el) Τροποποιητες toy trex1
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
BRPI0911031B8 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
CY1114045T1 (el) Φαρμακευτικη συνθεση με παρατεταμενη απελευθερωση οξικης οκτρεοτιδης
CY1115136T1 (el) Χρηση των χιτοζανων για την αυξηση του βαθμου αναπτυξης των νυχιων
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
TR201004464A2 (tr) Kemik erimesi için formülasyon.